text.skipToContent text.skipToNavigation
Need help? Please contact us

Human Peripheral Blood Mononuclear Cells (hPBMC), Cryopreserved, 25 million

Human Peripheral Blood Mononuclear Cells (hPBMC), Cryopreserved, 25 million

Catalog #: 4W-270A

Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 25 million cells.

 

Quantities of this part code may be limited, the following part code CC-2705 is recommended as an equivalent alternative.

Compare

Product Overview

Mononuclear cell (MNC) rich cells from leukapheresis are depleted of RBCs and platelets. MNC pools contain, on average, 50% T cells, 20% monocytes, 10% B cells, 10% NK cells and may contain up to 5% granulocytes. Cells are cryopreserved in Lonza cryopreservation media. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols.

Manufactured by AllCells®

Request More Info

Benefits

  • Test negative for mycoplasma, bacteria, yeast, and fungi
  • HIV-1, Hepatitis B and Hepatitis C are not detected for all donors and/or cell lots
  • Certificate of Analysis (CoA) is provided for each cell lot purchased

Applications

  • ELISPOT
  • Proliferation assays
  • Immunogenicity assays
  • Cell therapy process development
  • Humanized mice
  • Biomarker discovery

Storage and Content

1 x Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 25 million cells
Return to Top

SDS, CoA, and Instructions

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Return to Top

Educational Material

Brochures, White Papers etc.

  • Blood and Immune Cells

    Fueling your next discovery with unmatched cell and donor variety
  • An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cells

    A strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.
  • A Non-Viral Method for Modifying and Expanding Primary T Cells

    Learn how Lonza’s Cocoon® Platform, 4D-Nucleofector® LV Unit and X-VIVO® 15 Medium are integrated to enable non-viral genetic modification and subsequent expansion of primary T cells in a functionally-closed, automated workflow.
  • Procedure for thawing Poietics™ cells

Return to Top

Need a Quote or Any Support?

Request a local representative to get back to you with additional information or pricing.

Immunotherapy and Hematopoietic Knowledge Center

The Immunotherapy and Hematopoietic Knowledge Center is dedicated to sharing interesting articles and resources related to immuno and hematopoietic research.

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.